Under Rule 8.1

AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director

NORTH CHICAGO, Ill., March 2, 2020 /PRNewswire/ -- AbbVie issued the following forms today.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1.  KEY INFORMATION
Name of person dealing (Note 1)	AbbVie Inc.
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	28 February 2020

2.  INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
	Long			Short
	Number		(%)	Number		(%)
(1) Relevant securities	N/A
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	N/A
Total	N/A

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security:	Long			Short
	Number		(%)	Number		(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3.  DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Share buyback	2,452,782	$83.654

(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)

(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option	Writing, selling,  purchasing,  varying etc.	Number of securities  to which the option  relates (Note 7)	Exercise  price	Type, e.g. American,  European etc.	Expiry  date	Option money  paid/received  per unit (Note 5)

(ii) Exercising
Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4.  OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)	YES/NO?
Date of disclosure	2 March 2020
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	AbbVie Inc.

1. KEY INFORMATION
Name of person dealing  (Note 1)	Richard Gonzalez
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	21 February 2020

2.  INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
	Long			Short
	Number		(%)	Number		(%)
(1) Relevant securities	523,561 Common Shares (0.0004%)
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	1,161,286 options (0.0008%)
Total	1,684,847 (0.0011%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security:	Long			Short
	Number		(%)	Number		(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3.  DEALINGS  (Note 4)
(a) Purchases and sales
Purchase/sale	Number of relevant securities	Price per unit  (Note 5)
Issue of common shares pursuant to AbbVie equity award plans	200,262 common shares	$0
Gift of common shares	3,675 common shares	$0

(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)

(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option	Writing, selling,  purchasing,  varying etc.	Number of securities  to which the option  relates  (Note 7)	Exercise  price	Type, e.g.  American,  European etc.	Expiry  date	Option money  paid/received  per unit  (Note 5)

(ii) Exercising
Product name, e.g. call option	Number of securities	Exercise price per unit  (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4.  OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached?  (Note 9)	YES/NO?
Date of disclosure	2 March 2020
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

1.  KEY INFORMATION
Name of person dealing (Note 1)	Richard Gonzalez
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	28 February 2020

2.  INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
	Long			Short
	Number		(%)	Number		(%)
(1) Relevant securities	434,843 Common Shares (0.0004%)
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	1,161,286 options (0.0008%)
Total	1,596,128 (0.0011%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security:	Long			Short
	Number		(%)	Number		(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3.  DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale	Number of relevant securities		Price per unit (Note 5)
Withholding of common shares to satisfy tax obligations	88,719 common shares		$0
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)		Price per unit (Note 5)

(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option	Writing, selling,  purchasing,  varying etc.	Number of securities  to which the  option relates (Note 7)	Exercise  price	Type, e.g. American,  European etc.	Expiry  date	Option money  paid/received  per unit (Note 5)

(ii) Exercising
Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4.  OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)	YES/NO?
Date of disclosure	2 March 2020
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

CONTACT: Adelle Infante, 1-847-938-8745